Chemotherapy + PD-1/PD-L1 Blockade Should Not Be the Preferred Option in the Neoadjuvant Therapy of NSCLC

TY - JOUR

T1 - Chemotherapy + PD-1/PD-L1 Blockade Should Not Be the Preferred Option in the Neoadjuvant Therapy of NSCLC

AU - Hendriks, Lizza E.L.

AU - Remon, Jordi

AU - Reck, Martin

N1 - Funding Information: Disclosure: Dr. Hendriks reports no conflicts related to current manuscript and the following outside of current manuscript: research funding Roche Genentech , Boehringer Ingelheim , AstraZeneca (all institution, Takeda and BeiGene under negotiation); advisory board: Bristol-Myers Squibb , Eli Lilly, Roche Genentech , Pfizer , Takeda , Merck Sharp & Dohme , Boehringer Ingelheim , Amgen , Janssen (all institution, Roche one time self); speaker: Merck Sharp & Dohme , Eli Lilly (institution); travel/conference reimbursement: Roche Genentech (self); mentorship program with key opinion leaders: funded by AstraZeneca; fees for educational webinars: Benecke, Medtalks, VJOncology (self), high5oncology (institution); interview sessions funded by Roche Genentech , Bayer , Eli Lilly (institution); local principal investigators of clinical trials: AstraZeneca , Novartis , Bristol-Myers Squibb , Merck Sharp & Dohme / Merck , GlaxoSmithKline , Takeda , Blueprint Medicines, Roche Genentech , Janssen Pharmaceuticals , Mirati. Dr. Remon reports no conflicts related to current manuscript and the following outside of current manuscript: advisory board: Merck Sharp & Dohme, Boehringer Ingelheim, Bristol-Myers Squibb, AstraZeneca, Roche; Bayer. speaker: Pfizer; travel reimbursement: OSE Immunotherapeutics, Bristol-Myers Squibb, AstraZeneca, Roche. Dr. Reck reports no conflicts related to current manuscript and the following outside of current manuscript: honoraria for lectures and consultancy from Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, BeiGene, Bristol-Myers Squibb, Lilly, Merck, Merck Sharp & Dohme, Eli Lilly, Novartis, Pfizer, Roche, and Sanofi. Funding Information: Disclosure: Dr. Hendriks reports no conflicts related to current manuscript and the following outside of current manuscript: research funding Roche Genentech, Boehringer Ingelheim, AstraZeneca (all institution, Takeda and BeiGene under negotiation); advisory board: Bristol-Myers Squibb, Eli Lilly, Roche Genentech, Pfizer, Takeda, Merck Sharp & Dohme, Boehringer Ingelheim, Amgen, Janssen (all institution, Roche one time self); speaker: Merck Sharp & Dohme, Eli Lilly (institution); travel/conference reimbursement: Roche Genentech (self); mentorship program with key opinion leaders: funded by AstraZeneca; fees for educational webinars: Benecke, Medtalks, VJOncology (self), high5oncology (institution); interview sessions funded by Roche Genentech, Bayer, Eli Lilly (institution); local principal investigators of clinical trials: AstraZeneca, Novartis, Bristol-Myers Squibb, Merck Sharp & Dohme/Merck, GlaxoSmithKline, Takeda, Blueprint Medicines, Roche Genentech, Janssen Pharmaceuticals, Mirati. Dr. Remon reports no conflicts related to current manuscript and the following outside of current manuscript: advisory board: Merck Sharp & Dohme, Boehringer Ingelheim, Bristol-Myers Squibb, AstraZeneca, Roche; Bayer. speaker: Pfizer; travel reimbursement: OSE Immunotherapeutics, Bristol-Myers Squibb, AstraZeneca, Roche. Dr. Reck reports no conflicts related to current manuscript and the following outside of current manuscript: honoraria for lectures and consultancy from Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, BeiGene, Bristol-Myers Squibb, Lilly, Merck, Merck Sharp & Dohme, Eli Lilly, Novartis, Pfizer, Roche, and Sanofi.

PY - 2022/4/1

Y1 - 2022/4/1

UR - http://www.scopus.com/inward/record.url?scp=85126589559&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2021.11.024

DO - 10.1016/j.jtho.2021.11.024

M3 - Editorial

C2 - 35307106

AN - SCOPUS:85126589559

SN - 1556-0864

VL - 17

SP - 499

EP - 502

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 4

ER -